Active Biotech AB (ACTI) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Active Biotech AB stock SEK 2.31, price SEK 3.51, that is 34.2% below the price, quality 43 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Active Biotech AB
ACTI · STExpensive (fair value 34% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.
How to read this chart
60‑month range kr 3.11 – kr 46.36 · fair‑value band kr 1.73 – kr 2.88 · the kr 3.51 price screens above the kr 2.31 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.
Every Wednesday you see whether Active Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden.
Show moreShow less
It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors.
The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center.
The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Stock analysis
Active Biotech AB (ACTI) currently trades at kr 3.51, while our estimate is kr 2.31, 34% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: kr 1.73 (bear) to kr 2.88 (bull), the price of kr 3.51 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Active Biotech AB reported revenue of 0 SEK in FY2025 versus 6.2M SEK in FY2021. Reported net income was −37.3M SEK in FY2025.
Key figures
Market cap 92.5M SEK (≈ $9.2M) Micro · P/S ratio 15.2 · EPS (TTM) kr −1.70 · Return on equity −141% · Return on assets (EBIT) −90.5% (5-year average) · Revenue (TTM) 6.2M SEK · Revenue growth (YoY) +570% · Free cash flow −32.4M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 58% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −34%, ACTI screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Active Biotech AB with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/S ratio by industry
- EBIT margin by industry
- Piotroski F-Score screener with fair value
- Valuation of the Sweden market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs ACTI |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs ACTI |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs ACTI |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs ACTI |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs ACTI |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs ACTI |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs ACTI |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs ACTI |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs ACTI |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs ACTI |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Active Biotech AB (ACTI) overvalued or undervalued?
What is the fair value of ACTI?
What is the quality score of ACTI?
What is the price target for Active Biotech AB (ACTI)?
What is the Active Biotech AB stock forecast for 2026?
What is the revenue of Active Biotech AB (ACTI)?
What is the intrinsic value of Active Biotech AB (ACTI)?
Is Active Biotech AB stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ACTI?
How much is Active Biotech AB worth?
What do the bullish and bearish scenarios say about ACTI?
What is the PEG ratio of ACTI?
How solid is the balance sheet of Active Biotech AB (ACTI)?
How far is ACTI from its 52-week high?
Which stocks are comparable to Active Biotech AB?
Is Active Biotech AB stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Active Biotech AB (ACTI)?
What should I pay attention to with Active Biotech AB right now?
Key figures of Active Biotech AB
How large is the market capitalisation of Active Biotech AB (ACTI)?
What is the P/S ratio of Active Biotech AB (ACTI)?
What are the earnings per share of Active Biotech AB (ACTI)?
What is the return on equity of Active Biotech AB (ACTI)?
What is the EBIT return on assets of Active Biotech AB (ACTI)?
How fast is revenue growing at Active Biotech AB (ACTI)?
How much free cash flow does Active Biotech AB (ACTI) generate?
How much net cash does Active Biotech AB (ACTI) hold?
Watch Active Biotech AB in the live analysis
One click puts Active Biotech AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.